Printer Friendly

Enzyme dissolves cystic fibrosis phlegm.

An experimental drug that cystic fibrosis patients inhale in aerosol form can cut through the thick mucus that clogs their lungs, allowing them to breathe more easily and deeply, according to the results of a preliminary study.

A team led by National Institutes of Health researcher Ronald G. Crystal found that twice-daily inhalations of the drug, called DNase I, improved the lung functions of all 16 of the adult subjects. Moreover, the treatment had no noticeable side effects, the researchers report in the March 19 NEW ENGLAND JOURNAL OF MEDICINE.

DNase I is a naturally occurring body enzyme that chops up DNA, a major constituent of the sticky phlegm that accumulates in the lungs and other organs of cystic fibrosis patients. The DNA is left behind by infection-fighting white blood cells that migrate to the lining of these organs, only to die after finishing their job. Because DNA is very viscous, it makes the mucus hard to cough up, increasing patients' vulnerability to further lung infections.

DNase I treatment thinned the lung mucus of all of the patients participating in the new study, Crystal and his colleagues found. They also detected higher levels of degraded DNA in the patients' sputum following DNase I therapy.

"This is very exciting," says Robert J. Beall, vice president for medical affairs of the Cystic Fibrosis Foundation in Bethesda, Md. "It's the first [mucus-degrading drug] for which we've had such encouraging preliminary data."

Crystal and his colleagues reported early results from the DNase I study at a conference on cystic fibrosis last year (SN: 3/2/91, p.132). Genentech, Inc., the South San Francisco, Calif., biotechnology company that produces DNase I through genetic engineering, is now expanding tests of the drug to include 900 cystic fibrosis patients at 50 U.S. medical centers. If the additional tests confirm DNase I's efficacy, the company plans to file for Food and Drug Administration approval of the drug early next year.
COPYRIGHT 1992 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DNase
Publication:Science News
Article Type:Brief Article
Date:Apr 4, 1992
Words:324
Previous Article:Riding the rapids on Mars.
Next Article:Defect in cystic fibrosis protein found.
Topics:


Related Articles
Cystic fibrosis flaw reversed in vitro.
Genetic therapy: just a nasal spray away?
CF gene therapy on horizon.
Gene therapy for cystic fibrosis patients.
Gene therapy seeks to mend cystic fibrosis.
Cystic fibrosis: an antibiotic cure?
Cystic fibrosis controversy: a new theory hints that gene therapy in the womb can cure disease.
Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy.
The challenge of nontuberculous mycobacteria in patients with cystic fibrosis.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters